AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2382916 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% carboxyhemoglobin
Number of subjects: 41
Study 30987939 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg once daily) plus prednisone (5 mg once daily) and ADT
Number of subjects: 1199
Study 30987939 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ADT
Number of subjects: 1199
Study 30987939 — intervention group
Group type: COMPARATOR
Intervention: Crossover from placebo to abiraterone acetate plus prednisone
Number of subjects: 1199
Study 29807317 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA) plus risperidone
Number of subjects: 70
Study 29807317 — intervention group
Group type: COMPARATOR
Intervention: Risperidone plus placebo
Number of subjects: 70
Study 26469879 — intervention group
Group type: EXPERIMENTAL
Intervention: CSPs (n=161)
Number of subjects: 161
Study 26469879 — intervention group
Group type: COMPARATOR
Intervention: GPCs (n=355)
Number of subjects: 161
Study 24440327 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin therapy
Number of subjects: 350
Study 22908694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (FeSO₄) 100 mg
Number of subjects: 10
Study 22908694 — intervention group
Group type: COMPARATOR
Intervention: Sodium iron ethylenediaminetetraacetic acid (NaFeEDTA) 100 mg
Number of subjects: 10
Study 22908694 — intervention group
Group type: COMPARATOR
Intervention: Iron polymaltose 100 mg
Number of subjects: 10
Study 22908694 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 20976161 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 20
Study 20976161 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (3.2 g EPA and 2.0 g DHA)
Number of subjects: 20
Study 20976161 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Montelukast + Fish oil)
Number of subjects: 20
Study 20976161 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (pre-treatment)
Number of subjects: 20
Study 20976161 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Montelukast, Fish oil, Combination)
Number of subjects: 20
Study 20976161 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil and Combination treatment
Number of subjects: 20
Study 17449571 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain wheat bread
Number of subjects: 15
Study 17449571 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain rye crisp bread
Number of subjects: 15
Study 17449571 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain rye diet
Number of subjects: 15
Study 17449571 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain rye intake
Number of subjects: 15
Study 17449571 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat bread
Number of subjects: 15
Study 16022854 — intervention group
Group type: COMPARATOR
Intervention: Depo-Provera
Number of subjects: 360
Study 16022854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofem
Number of subjects: 360
Study 11963645 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Dilavenil)
Number of subjects: 20
Study 11963645 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 20
Study 9811158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg once daily for 8 days
Number of subjects: 12
Study 9811158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg once daily for 8 days
Number of subjects: 12
Study 9811158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 150 mg once daily for 8 days
Number of subjects: 12
Study 9811158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 200 mg once daily for 8 days
Number of subjects: 12
Study 9811158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 40 mg intravenous dose
Number of subjects: 12
Study 9811158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 100, 150, or 250 mg oral multiple-dose
Number of subjects: 12
Study 9811158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg and 100 mg once daily
Number of subjects: 12
Study 7658777 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise test (positive result)
Number of subjects: 6296
Study 7658777 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise test (negative result)
Number of subjects: 6296
Study 7658777 — intervention group
Group type: COMPARATOR
Intervention: No exercise test
Number of subjects: 6296
Study 7658777 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diagnostic test
Number of subjects: 6296
Study 7658777 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic induced ischaemia
Number of subjects: 6296
Study 7658777 — intervention group
Group type: EXPERIMENTAL
Intervention: Low work capacity
Number of subjects: 6296
Study 2522756 — intervention group
Group type: EXPERIMENTAL
Intervention: Organoclay preparation
Number of subjects: 0
Study 2522756 — intervention group
Group type: COMPARATOR
Intervention: Bentonite
Number of subjects: 0
Study 2522756 — intervention group
Group type: COMPARATOR
Intervention: Kaolin
Number of subjects: 0
Study 2522756 — intervention group
Group type: COMPARATOR
Intervention: Silicone
Number of subjects: 0
Study 79709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide and oxygen for 24 hours
Number of subjects: 22
Study 79709 — intervention group
Group type: COMPARATOR
Intervention: No nitrous oxide
Number of subjects: 22
Study 79709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide during the operation only
Number of subjects: 22
Study 31869530 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider communication intervention
Number of subjects: 98
Study 30519872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training (five 60-min sessions per week for 12 weeks)
Number of subjects: 170
Study 30519872 — intervention group
Group type: COMPARATOR
Intervention: Usual physical activity (control group for 12 weeks)
Number of subjects: 170
Study 29150457 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA + sucrose + ring block (RB)
Number of subjects: 70
Study 29150457 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA + sucrose + dorsal penile nerve block (DPNB)
Number of subjects: 70
Study 29150457 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA + sucrose
Number of subjects: 70
Study 29150457 — intervention group
Group type: COMPARATOR
Intervention: EMLA alone
Number of subjects: 70
Study 26225995 — intervention group
Group type: EXPERIMENTAL
Intervention: Black Bean (BB) meal
Number of subjects: 12
Study 26225995 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant Matched (AM) meal
Number of subjects: 12
Study 26225995 — intervention group
Group type: COMPARATOR
Intervention: Fiber Matched (FM) meal
Number of subjects: 12
Study 26225995 — intervention group
Group type: EXPERIMENTAL
Intervention: All meals
Number of subjects: 12
Study 23477478 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + PCT
Number of subjects: 187
Study 23477478 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 187
Study 21052768 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal arm-ergometry
Number of subjects: 0
Study 21052768 — intervention group
Group type: COMPARATOR
Intervention: Maximal leg-ergometry
Number of subjects: 0
Study 21052768 — intervention group
Group type: COMPARATOR
Intervention: Sub-maximal leg-ergometry
Number of subjects: 0
Study 18768048 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone plus propofol
Number of subjects: 80
Study 18768048 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone alone
Number of subjects: 80
Study 15819763 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw thrust
Number of subjects: 50
Study 15819763 — intervention group
Group type: COMPARATOR
Intervention: Conventional Macintosh laryngoscopy
Number of subjects: 50
Study 12441211 — intervention group
Group type: EXPERIMENTAL
Intervention: lercanidipine 10 mg/day
Number of subjects: 828
Study 12441211 — intervention group
Group type: COMPARATOR
Intervention: amlodipine 5 mg/day
Number of subjects: 828
Study 12441211 — intervention group
Group type: EXPERIMENTAL
Intervention: lacidipine 2 mg/day
Number of subjects: 828
Study 10527003 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Rating Frenchay Activities Index (activity index)
Number of subjects: 752
Study 10527003 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Rating Barthel Index (disability index)
Number of subjects: 752
Study 7723950 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg rt-PA
Number of subjects: 23
Study 7723950 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg rt-PA
Number of subjects: 23
Study 7723950 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (150 mg or 100 mg)
Number of subjects: 23
Study 11542203 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 4
Study 11542203 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 4
Study 11542203 — intervention group
Group type: COMPARATOR
Intervention: Astemizole
Number of subjects: 4
Study 11542203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 6779303 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormethiazole (1 g at bedtime and 0.5 g early the following morning)
Number of subjects: 12
Study 6779303 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo tablets
Number of subjects: 12
Study 6779303 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption (1.43 g alcohol/kg body weight)
Number of subjects: 12
Study 6779303 — intervention group
Group type: COMPARATOR
Intervention: Control session (mineral water)
Number of subjects: 12
Study 31818847 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine administration
Number of subjects: 192
Study 31818847 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid administration or titration
Number of subjects: 192
Study 29531748 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPPORT intervention
Number of subjects: 64
Study 29531748 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 64
Study 27469437 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Teeth (AT) training (n=20)
Number of subjects: 43
Study 27469437 — intervention group
Group type: COMPARATOR
Intervention: Natural Teeth (NT) training (n=23)
Number of subjects: 43
Study 25602710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepicastat 80mg
Number of subjects: 13
Study 25602710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepicastat 160mg
Number of subjects: 13
Study 25602710 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0mg)
Number of subjects: 13
Study 23684138 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Group 1, n = 133)
Number of subjects: 411
Study 23684138 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (500 mg) 1 hour before procedure (Group 2, n = 141)
Number of subjects: 411
Study 23684138 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of fosfomycin tromethamine (FT) approximately 12 hours before procedure (Group 3, n = 137)
Number of subjects: 411
Study 21903370 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbicort® (SYM100)
Number of subjects: 10
Study 21903370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21903370 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD200)
Number of subjects: 10
Study 21903370 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD800)
Number of subjects: 10
Study 21903370 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbicort® (SYM200)
Number of subjects: 10
Study 19164833 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 13
Study 19164833 — intervention group
Group type: COMPARATOR
Intervention: Placebo (flour)
Number of subjects: 13
Study 16914412 — intervention group
Group type: EXPERIMENTAL
Intervention: Retransfusion of pericardial suction blood during CPB (Group A)
Number of subjects: 35
Study 16914412 — intervention group
Group type: COMPARATOR
Intervention: No retransfusion of pericardial suction blood during CPB (Group B)
Number of subjects: 35
Study 15358704 — intervention group
Group type: EXPERIMENTAL
Intervention: Home cardiorespiratory polygraphy
Number of subjects: 75
Study 10930321 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium (50 mg)
Number of subjects: 40
Study 10930321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9049678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide 4 micrograms/kg i.v. (n=33)
Number of subjects: 98
Study 9049678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide 8 micrograms/kg i.v. (n=32)
Number of subjects: 98
Study 9049678 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=33)
Number of subjects: 98
Study 8295040 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-site health promotion programs for weight control and smoking cessation
Number of subjects: 32
Study 8295040 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation programs
Number of subjects: 32
Study 8295040 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight control programs
Number of subjects: 32
Study 8295040 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline smokers
Number of subjects: 32
Study 3554415 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% mepivacaine
Number of subjects: 40
Study 3554415 — intervention group
Group type: COMPARATOR
Intervention: 1.5% prilocaine
Number of subjects: 40
Study 29743071 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line coil treatment
Number of subjects: 0
Study 29743071 — intervention group
Group type: COMPARATOR
Intervention: Second-line coil treatment
Number of subjects: 0
Study 30226361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve decompression
Number of subjects: 0
Study 30226361 — intervention group
Group type: COMPARATOR
Intervention: No nerve decompression (Control)
Number of subjects: 0
Study 24912465 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially anxious individuals (SAD)
Number of subjects: 80
Study 24912465 — intervention group
Group type: COMPARATOR
Intervention: Non-socially-anxious participants
Number of subjects: 80
Study 22387644 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg orally 2 hours prior to surgery
Number of subjects: 70
Study 22387644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 19702474 — intervention group
Group type: EXPERIMENTAL
Intervention: Conceptual priming with obscure words that elicited meaningful associations
Number of subjects: 0
Study 19702474 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity-based recognition with late posterior potentials
Number of subjects: 0
Study 19702474 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity-based recognition with FN400 potentials
Number of subjects: 0
Study 19702474 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition tests with repeated stimuli
Number of subjects: 0
Study 19213339 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐F (chemotherapy with FOLFOX protocol)
Number of subjects: 61
Study 19213339 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐F combined with HM
Number of subjects: 61
Study 19213339 — intervention group
Group type: COMPARATOR
Intervention: HM (herbal medicines for reinforcing Shen and supplementing qi)
Number of subjects: 61
Study 19213339 — intervention group
Group type: COMPARATOR
Intervention: Blank control group (D)
Number of subjects: 61
Study 15908833 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-administered, abstinence-based incentive program; parent-directed contingency management; clinic-administered incentive program for parent participation; individual cognitive-behavioral therapy
Number of subjects: 19
Study 15908833 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-directed contingency management targeting substance use and conduct problems
Number of subjects: 19
Study 15908833 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy for adolescents
Number of subjects: 19
Study 12620167 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 4 g/d
Number of subjects: 0
Study 10719262 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) applied to frontal and parietal scalp sites of the unaffected hemisphere
Number of subjects: 30
Study 10719262 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of digits using a dedicated electronic device
Number of subjects: 30
Study 8791076 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal crescentic osteotomy
Number of subjects: 75
Study 8791076 — intervention group
Group type: COMPARATOR
Intervention: Proximal chevron osteotomy
Number of subjects: 75
Study 1539816 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal piroxicam (40 mg 12 h before surgery, 20 mg with premedication, and 20 mg every 24 h for 72 h)
Number of subjects: 44
Study 1539816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 3890506 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (40 mg orally)
Number of subjects: 18
Study 3890506 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg orally)
Number of subjects: 18
Study 30464430 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowering self-management model
Number of subjects: 60
Study 30464430 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 26579854 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 20
Study 26579854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22984818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder filling with normal saline prior to trial of void (up to 500 mL or first sensation of fullness)
Number of subjects: 52
Study 22984818 — intervention group
Group type: COMPARATOR
Intervention: Control group (catheter removed at 06:00 hours without filling)
Number of subjects: 52
Study 21952714 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation (19 weeks)
Number of subjects: 85
Study 21952714 — intervention group
Group type: COMPARATOR
Intervention: Nonaccelerated rehabilitation (32 weeks)
Number of subjects: 85
Study 21952714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both accelerated and nonaccelerated rehabilitation
Number of subjects: 85
Study 19082693 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day for 12 weeks
Number of subjects: 69
Study 19082693 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day for 12 weeks
Number of subjects: 69
Study 17686555 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV peptide-vaccine IC41 (includes 5 MHC-class I and 3 MHC class-II-restricted epitopes)
Number of subjects: 0
Study 17686555 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV peptide-vaccine IC41
Number of subjects: 0
Study 15508562 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patients and telemedicine
Number of subjects: 0
Study 15508562 — intervention group
Group type: COMPARATOR
Intervention: Traditional distance learning
Number of subjects: 0
Study 11975770 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 9023090 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (33 degrees C for 24 hours)
Number of subjects: 82
Study 9023090 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (control group)
Number of subjects: 82
Study 9023090 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (for patients with coma scores of 5 to 7)
Number of subjects: 82
Study 9023090 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia
Number of subjects: 82
Study 7942475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary phentolamine, 2 mg, infused regionally through the balloon catheter before coronary artery angioplasty (n=12)
Number of subjects: 32
Study 7942475 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 32
Study 2894161 — intervention group
Group type: EXPERIMENTAL
Intervention: rilmenidine (0.5 mg)
Number of subjects: 18
Study 2894161 — intervention group
Group type: EXPERIMENTAL
Intervention: rilmenidine (1 mg)
Number of subjects: 18
Study 2894161 — intervention group
Group type: EXPERIMENTAL
Intervention: rilmenidine (2 mg)
Number of subjects: 18
Study 2894161 — intervention group
Group type: EXPERIMENTAL
Intervention: rilmenidine (3 mg)
Number of subjects: 18
Study 2894161 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 29700944 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct exercise supervision
Number of subjects: 50
Study 29700944 — intervention group
Group type: COMPARATOR
Intervention: No direct exercise supervision
Number of subjects: 50
Study 28777259 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stress condition (modified Trier Social Stress Test)
Number of subjects: 0
Study 28777259 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 26286147 — intervention group
Group type: EXPERIMENTAL
Intervention: Qing-Feng-Gan-Ke Granules (QFGKG) 12.0 g twice daily
Number of subjects: 480
Study 26286147 — intervention group
Group type: COMPARATOR
Intervention: Placebo 12.0 g twice daily
Number of subjects: 480
Study 22729212 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose NRT (31.2 mg for the first 4 weeks, then 20.8 mg for 4 weeks)
Number of subjects: 184
Study 22729212 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose NRT (20.8 mg for 8 weeks)
Number of subjects: 184
Study 21365172 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 19
Study 21365172 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 19
Study 21365172 — intervention group
Group type: COMPARATOR
Intervention: Emollient
Number of subjects: 19
Study 21365172 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 19
Study 18294500 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rosuvastatin (5 mg)
Number of subjects: 43
Study 18294500 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rosuvastatin (40/80 mg)
Number of subjects: 43
Study 18294500 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43